JDRF and Becton, Dickinson and Company (BD) are accelerating the development of new products that combine BD’s insulin infusion and glucose sensing technologies through a new three-year collaboration.
This commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes (T1D), an autoimmune disease in which the body’s pancreas stops producing insulin – a hormone needed to turn food into energy.
Although BD has been working to improve the products used for insulin infusion and continuous glucose monitor, the new collaboration with JDRF will extend further research to develop a single optimized device that can perform both functions and remove the requirement and complexities of multiple in-dwelling catheters.
Artificial pancreas concept is defined when metabolic actions can be done automatically and accurately with no patient intervention.
BD Medical Diabetes Care president Linda Tharby said providing the best tools that not only improve patient care, but ease the daily burden of managing diabetes are important goals for BD and JDRF.
"This latest collaboration with JDRF demonstrates both parties’ commitment to improve patients’ experiences and outcomes.
"Combining these novel technologies will address two key components of an advanced artificial pancreas system," Tharby added.
JDRF president and CEO Jeffrey Brewer said, "We are excited to continue our collaboration with BD and support efforts to develop novel technologies enabling advanced artificial pancreas systems that will both measure glucose and administer insulin."
"Joining these capabilities into a single solution will address significant patient needs and help reduce the daily burden of managing of type 1 diabetes," Brewer added.